Rche sur le Syst e Nerveux Central (GRSNC) (M.B., L.
Rche sur le Syst e Nerveux Central (GRSNC) (M.B., L.L., D.V., H.G.); and Centre interdisciplinaire de recherche sur le cerveau et l’apprentissage (CIRCA) (D.V., H.G.), Universitde Montr l, Montr l, Qu ec, Canada; and Centre de Recherche de l’Institut de G iatrie de Montr l, Montr l, Qu ec, Canada (H.G.).13.14.15.Sources of FundingThis study was supported by the Heart and Stroke Foundation of Canada (HSFC), Fonds de Recherche du Qu ec-Sant(FRQS), the Canada Foundation for Innovation (CFI), and also the Canadian Institutes of Health Analysis (CIHR). H e Girouard was also the holder of a new investigator award from the FRQS as well as the HSFC.16.DisclosuresNone.17.Supplementary MaterialFigures S1S18.
Circulation Reports Circ Rep 2021; 3: 504 510 doi: ten.1253/circrep.CR-21-ORIGINAL ARTICLECardiovascular InterventionTORII S et al.Antiplatelet Effect of Single Antiplatelet Therapy With prasugrel and Oral Anticoagulation NPY Y2 receptor Activator Purity & Documentation Following Stent Implantation within a Rabbit Arteriovenous Shunt ModelSho Torii, MD, PhD; Tadashi Yamamoto, MD, PhD; Norihito Nakamura, MD; Takeshi Ijichi, MD, PhD; Ayako Yoshikawa; Yusuke Ito, PhD; Atsuhiro Sugidachi, PhD; Yuji Ikari, MD; Gaku Nakazawa, MD, PhDBackground: Antiplatelet therapy following stent implantation in individuals requiring oral anticoagulation (OAC) is controversial due to the fact triple therapy (i.e., dual antiplatelet therapy [DAPT] with OAC) is related using a higher risk of bleeding. Approaches and Results: In this study, 21 rabbits were divided into 5 groups: prasugrel and warfarin (Prasugrel+OAC group); aspirin and warfarin (Aspirin+OAC group); prasugrel, aspirin, and warfarin group (Triple group); prasugrel and aspirin (Standard DAPT group); and no medication (Handle group). The treated groups were administered medication for 1 week. An arteriovenous shunt loop was established from the rabbit carotid artery to the jugular vein and 2 bare metal stents had been deployed within a silicone tube. Following 1 h of circulation, the volume of thrombi was evaluated quantitatively by MEK1 Inhibitor site measuring the level of protein. Bleeding time was measured in the exact same time. The volume from the thrombus (amount of protein) about stent struts was lowest inside the Triple group, followed by the Prasugrel+OAC and Traditional DAPT groups, and was highest inside the Handle group. Bleeding time was the longest within the Triple group, followed by the Aspirin+OAC, Prasugrel+OAC, Standard DAPT, and Manage groups. Conclusions: This study suggests that prasugrel with OAC might be a feasible antithrombotic regimen following stent implantation in individuals who need OAC therapy. Essential Words: Atrial fibrillation; Dual antiplatelet therapy; Oral anticoagulant therapy; Percutaneous coronary intervention; Stent thrombosisual antiplatelet therapy (DAPT) with aspirin and also a P2Y12 receptor inhibitor has come to be the gold common following percutaneous coronary intervention (PCI) to prevent stent thrombosis (ST).1 Using the number of sufferers with atrial fibrillation (AF) escalating, it was recently reported that around ten of patients who underwent PCI had AF.2 Triple therapy, consisting of DAPT plus oral anticoagulants (OAC), had been advisable to stop each ST and cardiogenic embolism. Nonetheless, current randomized manage studies (RCTs) comparing triple therapy and dual therapy with an OAC and P2Y12 receptor inhibitor have demonstrated a important reduction in bleeding events too as related danger of ST.three Therefore, the most recent Japanese guideline recommends triple therapy through.
